{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-11781"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-11781","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Immunogenicity of a <em>Plasmodium vivax</em> Circumsporozoite Protein Vaccine","abstract":"Malaria is a disease of global public health importance. Improving treatment methods focus on novel antimalarial drugs to combat parasite resistance and the development of vaccines with effective adjuvants. The current vaccine RTS,S/AS01 is moderately effective only against Plasmodium falciparum. There is no vaccine for Plasmodium vivax to date. The development and implementation of a vaccine against P. vivax would inhibit sporozoite infection of hepatocytes, block development into the blood stage and confer future immune protection. The circumsporozoite protein (CSP) is the most abundant on the surface of sporozoites and protein variants VK210 and VK247 are leading vaccine candidates for P. vivax. To evaluate their immunogenicity, recombinant CSP antigens were produced for murine immunizations, followed by serological assays and antibody affinity purification. Producing high titers of antibodies that are strain transcending, broadly neutralizing and long lasting can prevent vivax malaria infection and reduce its transmission.","abstract_html":"Malaria is a disease of global public health importance. Improving treatment methods focus on novel antimalarial drugs to combat parasite resistance and the development of vaccines with effective adjuvants. The current vaccine RTS,S/AS01 is moderately effective only against Plasmodium falciparum. There is no vaccine for Plasmodium vivax to date. The development and implementation of a vaccine against P. vivax would inhibit sporozoite infection of hepatocytes, block development into the blood stage and confer future immune protection. The circumsporozoite protein (CSP) is the most abundant on the surface of sporozoites and protein variants VK210 and VK247 are leading vaccine candidates for P. vivax. To evaluate their immunogenicity, recombinant CSP antigens were produced for murine immunizations, followed by serological assays and antibody affinity purification. Producing high titers of antibodies that are strain transcending, broadly neutralizing and long lasting can prevent vivax malaria infection and reduce its transmission.","abstract_has_math":false,"creators":["Cruz Murphy, Eric"],"institution":"University of South Florida","degree_name":"MS in Public Health (M.S.P.H.)","degree_level":"Thesis","degree_discipline":"Global Health","degree_department":null,"school":null,"contributors":["John H. Adams, Ph.D.","Francis Ntumngia, Ph.D.","Dipak Raj, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-06-21T07:00:00Z","date_published":"2024-06-21T07:00:00Z","updated_at":"2026-11-19T08:50:14Z","subjects":["antibody purification","CSP","malaria vaccine","molecular parasitology","Public Health"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/10494","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/10494","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-11781","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["John H. Adams, Ph.D.","Francis Ntumngia, Ph.D.","Dipak Raj, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Cruz Murphy, Eric"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-06-21T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Global Health"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis","M.S.P.H."]},{"key":"thesis:degree_name","label":"Degree Name","values":["MS in Public Health (M.S.P.H.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["antibody purification","CSP","malaria vaccine","molecular parasitology","Public Health"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights.license","label":"Dc Rights License","values":["default"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/10494"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Malaria is a disease of global public health importance. Improving treatment methods focus on novel antimalarial drugs to combat parasite resistance and the development of vaccines with effective adjuvants. The current vaccine RTS,S/AS01 is moderately effective only against Plasmodium falciparum. There is no vaccine for Plasmodium vivax to date. The development and implementation of a vaccine against P. vivax would inhibit sporozoite infection of hepatocytes, block development into the blood stage and confer future immune protection. The circumsporozoite protein (CSP) is the most abundant on the surface of sporozoites and protein variants VK210 and VK247 are leading vaccine candidates for P. vivax. To evaluate their immunogenicity, recombinant CSP antigens were produced for murine immunizations, followed by serological assays and antibody affinity purification. Producing high titers of antibodies that are strain transcending, broadly neutralizing and long lasting can prevent vivax malaria infection and reduce its transmission."]},{"key":"dc:title","label":"Title","values":["Immunogenicity of a <em>Plasmodium vivax</em> Circumsporozoite Protein Vaccine"]}]}],"canonical_facts":{"dc:contributor":["John H. Adams, Ph.D.","Francis Ntumngia, Ph.D.","Dipak Raj, Ph.D."],"dc:creator":["Cruz Murphy, Eric"],"dc:date":["2024-06-21T07:00:00Z"],"dc:description":["Malaria is a disease of global public health importance. Improving treatment methods focus on novel antimalarial drugs to combat parasite resistance and the development of vaccines with effective adjuvants. The current vaccine RTS,S/AS01 is moderately effective only against Plasmodium falciparum. There is no vaccine for Plasmodium vivax to date. The development and implementation of a vaccine against P. vivax would inhibit sporozoite infection of hepatocytes, block development into the blood stage and confer future immune protection. The circumsporozoite protein (CSP) is the most abundant on the surface of sporozoites and protein variants VK210 and VK247 are leading vaccine candidates for P. vivax. To evaluate their immunogenicity, recombinant CSP antigens were produced for murine immunizations, followed by serological assays and antibody affinity purification. Producing high titers of antibodies that are strain transcending, broadly neutralizing and long lasting can prevent vivax malaria infection and reduce its transmission."],"dc:identifier":["https://digitalcommons.usf.edu/etd/10494"],"dc:rights.license":["default"],"dc:subject":["antibody purification","CSP","malaria vaccine","molecular parasitology","Public Health"],"dc:title":["Immunogenicity of a <em>Plasmodium vivax</em> Circumsporozoite Protein Vaccine"],"thesis:degree_discipline":["Global Health"],"thesis:degree_level":["Thesis","M.S.P.H."],"thesis:degree_name":["MS in Public Health (M.S.P.H.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:50:14Z"}